Anhydrous amorphous imatinib mesylate

Details Anhydrous amorphous imatinib mesylate Anhydrous amorphous imatinib mesylate

2011-05-24

2011-05-24

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C424S464000, C544S331000, C544S364000, C546S268100

Reexamination Certificate

active

07947699

ABSTRACT:
Described is a highly stable amorphous form of imatinib mesylate having a water content of less than 0.5 percent by weight, based on the total weight of the amorphous imatinib mesylate, (anhydrous amorphous imatinib mesylate), a process for preparation thereof, and pharmaceutical compositions.

REFERENCES:
patent: 5521184 (1996-05-01), Zimmermann
patent: 7300938 (2007-11-01), Parthasaradhi et al.
patent: 2005077933 (2005-08-01), None
patent: 2005095379 (2005-10-01), None
patent: 2006024863 (2006-03-01), None
patent: 2006048890 (2006-05-01), None
patent: 2006054314 (2006-05-01), None
patent: 2007023182 (2007-03-01), None
patent: 2007136510 (2007-11-01), None
patent: WO 2007/136510 (2007-11-01), None
Konno, Tsutomu; “Physical and Chemical Changes of Medicinals in Mixtures with Adsorbents in the Solid State. IV. Study on Reduced-Pressure Mixing for Practical Use of Amorphous Mixtures of Flufenamic Acid”; Chem. Pharm. Bull.; 38; pp. 2003-2007; (1990).

Affiliated with

Also associated with

Rating

Anhydrous amorphous imatinib mesylate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anhydrous amorphous imatinib mesylate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anhydrous amorphous imatinib mesylate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2700903